Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Early Obesity Research Finds Leptin Hormone May Not Be Overeating Culprit

By Drug Discovery Trends Editor | May 15, 2015

Assistant Professor Diego Perez-Tilve (University of Cinncinnati)For years, scientists have pointed to leptin resistance as a possible cause of obesity. Research led by investigators at the University of Cincinnati (UC) Metabolic Diseases Institute, however, found that leptin action isn’t the culprit.
 
“Restoring leptin action will not be effective at reducing obesity because leptin action is normal as opposed to being impaired in obesity,” says assistant professor Diego Perez-Tilve, PhD, who directed the study “Diet-Induced Obese Mice Retain Endogenous Leptin Action” which appeared in the science journal Cell Metabolism.
 
Leptin is a hormone that plays a role in appetite and weight control. It is produced, Perez-Tilve says, when we are well fed, and it signals to the brain that there is ample energy and therefore reduces eating.
 
Leptin has been a hormone of interest since 1994, he says, when scientists discovered that a particular strain of obese mouse couldn’t produce leptin at all.
 
“That mouse was very obese because it was hungry all the time. When they treated the mouse withleptin, it stopped eating so much and started losing weight.”
 
Perez-Tilve says scientists were initially puzzled because obese persons have leptin levels far higher than persons of average weight. They theorized that the body was making extra leptin to combat obesity and that the obese patients must therefore need more leptin than persons of average weight to signal the brain to stop eating. However, in human preclinical trials, “giving obese patients more leptin didn’t work … they ate the same and remained obese, so it was concluded that obesity was a state of leptin resistance,” he says.
 
In the UC study, funded by the National Institutes of Health, the team headed by Perez-Tilve took a different approach. They blocked leptin action in both lean and obese mice. The results were that both sets of mice ate more and gained weight to the same extent, proving that “leptin action was not impaired in the obese mouse.”
 
With obesity affecting more than one-third of Americans and taking a toll on the nation’s health care system, Perez-Tilve says the results of this study show “we need to change our way of thinking about how to use leptin as a potential target for therapy to treat obesity.”
 
Source: University of Cincinnati

Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE